| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 87 | 2024 | 11538 | 3.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 39 | 2023 | 5319 | 1.830 |
Why?
|
| Small Cell Lung Carcinoma | 14 | 2023 | 406 | 1.660 |
Why?
|
| Receptors, G-Protein-Coupled | 9 | 2022 | 488 | 1.550 |
Why?
|
| Adenocarcinoma | 36 | 2023 | 7789 | 1.390 |
Why?
|
| Biomarkers, Tumor | 30 | 2024 | 10331 | 0.830 |
Why?
|
| Precancerous Conditions | 11 | 2024 | 1058 | 0.820 |
Why?
|
| Nitrosamines | 4 | 2022 | 50 | 0.790 |
Why?
|
| Immunohistochemistry | 27 | 2023 | 7548 | 0.710 |
Why?
|
| Carcinogens | 6 | 2024 | 384 | 0.650 |
Why?
|
| Lung | 15 | 2023 | 3151 | 0.570 |
Why?
|
| Genetic Heterogeneity | 8 | 2021 | 318 | 0.570 |
Why?
|
| Cell Transformation, Neoplastic | 10 | 2019 | 2359 | 0.560 |
Why?
|
| Pleural Neoplasms | 5 | 2020 | 470 | 0.540 |
Why?
|
| Genomics | 10 | 2021 | 2738 | 0.540 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1331 | 0.540 |
Why?
|
| Bronchi | 2 | 2018 | 326 | 0.520 |
Why?
|
| Tumor Microenvironment | 16 | 2023 | 2864 | 0.490 |
Why?
|
| Respiratory Mucosa | 3 | 2012 | 206 | 0.490 |
Why?
|
| Transcriptome | 7 | 2023 | 1859 | 0.470 |
Why?
|
| Adenocarcinoma in Situ | 2 | 2023 | 31 | 0.430 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1586 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 23 | 2021 | 8873 | 0.420 |
Why?
|
| DNA Methylation | 8 | 2021 | 2669 | 0.400 |
Why?
|
| Humans | 115 | 2024 | 261506 | 0.390 |
Why?
|
| B7-H1 Antigen | 9 | 2023 | 1022 | 0.390 |
Why?
|
| Mesothelioma | 4 | 2018 | 544 | 0.380 |
Why?
|
| Mutation | 23 | 2024 | 15179 | 0.380 |
Why?
|
| Thymus Neoplasms | 4 | 2018 | 400 | 0.370 |
Why?
|
| Nuclear Proteins | 7 | 2022 | 3343 | 0.370 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2019 | 1064 | 0.360 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2022 | 607 | 0.340 |
Why?
|
| Carboplatin | 3 | 2021 | 823 | 0.340 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1021 | 0.330 |
Why?
|
| Smoking | 9 | 2020 | 2440 | 0.330 |
Why?
|
| Thymoma | 3 | 2018 | 246 | 0.320 |
Why?
|
| Prognosis | 23 | 2022 | 21713 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1648 | 0.310 |
Why?
|
| Cell Lineage | 5 | 2021 | 668 | 0.310 |
Why?
|
| Gene Expression Profiling | 13 | 2022 | 5159 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 992 | 0.310 |
Why?
|
| Neoplasm Staging | 18 | 2023 | 13658 | 0.300 |
Why?
|
| Drug Synergism | 1 | 2010 | 1313 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 10035 | 0.290 |
Why?
|
| Transcription Factors | 8 | 2022 | 5270 | 0.280 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 4 | 2020 | 479 | 0.270 |
Why?
|
| Aged | 42 | 2023 | 70117 | 0.270 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2021 | 716 | 0.270 |
Why?
|
| Models, Statistical | 2 | 2019 | 1171 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 15862 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2020 | 419 | 0.270 |
Why?
|
| Dasatinib | 2 | 2020 | 862 | 0.260 |
Why?
|
| Middle Aged | 44 | 2022 | 86204 | 0.260 |
Why?
|
| Male | 54 | 2023 | 123000 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2021 | 5437 | 0.260 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2004 | 25 | 0.250 |
Why?
|
| Tobacco Products | 2 | 2024 | 120 | 0.250 |
Why?
|
| Female | 55 | 2023 | 141928 | 0.250 |
Why?
|
| Carcinogenesis | 5 | 2023 | 1026 | 0.240 |
Why?
|
| Circulating MicroRNA | 1 | 2024 | 25 | 0.240 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2020 | 1823 | 0.240 |
Why?
|
| Neoplasm Proteins | 7 | 2021 | 3230 | 0.240 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 3869 | 0.230 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2018 | 973 | 0.230 |
Why?
|
| Mediastinal Neoplasms | 2 | 2019 | 423 | 0.220 |
Why?
|
| DNA Copy Number Variations | 5 | 2021 | 1516 | 0.220 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 529 | 0.220 |
Why?
|
| Water Pipe Smoking | 1 | 2022 | 2 | 0.220 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 354 | 0.220 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2018 | 519 | 0.220 |
Why?
|
| DNA-Binding Proteins | 10 | 2022 | 4821 | 0.220 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 216 | 0.210 |
Why?
|
| Mice, Knockout | 8 | 2019 | 5710 | 0.210 |
Why?
|
| Hyperplasia | 5 | 2023 | 557 | 0.210 |
Why?
|
| Membrane Proteins | 4 | 2019 | 2819 | 0.210 |
Why?
|
| Evolution, Molecular | 3 | 2023 | 834 | 0.200 |
Why?
|
| Stomach Neoplasms | 8 | 2004 | 2278 | 0.200 |
Why?
|
| Cisplatin | 5 | 2021 | 2432 | 0.200 |
Why?
|
| Neuroendocrine Tumors | 2 | 2021 | 634 | 0.200 |
Why?
|
| Genome, Human | 4 | 2020 | 1869 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2022 | 69 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 361 | 0.200 |
Why?
|
| Mice | 17 | 2024 | 34495 | 0.200 |
Why?
|
| Proteoglycans | 1 | 2022 | 259 | 0.190 |
Why?
|
| CD3 Complex | 1 | 2022 | 314 | 0.190 |
Why?
|
| Lipocalin-2 | 1 | 2021 | 65 | 0.190 |
Why?
|
| Algorithms | 4 | 2023 | 3890 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 1678 | 0.190 |
Why?
|
| Vesicular Transport Proteins | 1 | 2022 | 135 | 0.190 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 518 | 0.190 |
Why?
|
| Benzimidazoles | 2 | 2021 | 428 | 0.190 |
Why?
|
| Adult | 29 | 2023 | 77950 | 0.180 |
Why?
|
| Cell Line, Tumor | 13 | 2022 | 14551 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 2232 | 0.180 |
Why?
|
| Allelic Imbalance | 2 | 2019 | 41 | 0.180 |
Why?
|
| Bites and Stings | 1 | 2020 | 44 | 0.180 |
Why?
|
| Ipilimumab | 2 | 2023 | 710 | 0.180 |
Why?
|
| Hematoxylin | 3 | 2023 | 34 | 0.180 |
Why?
|
| DNA Repair Enzymes | 2 | 2018 | 237 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 7 | 2023 | 4975 | 0.180 |
Why?
|
| Oncogenes | 2 | 2014 | 673 | 0.170 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 14289 | 0.170 |
Why?
|
| Cell Proliferation | 7 | 2019 | 7226 | 0.170 |
Why?
|
| ErbB Receptors | 6 | 2023 | 2295 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 1833 | 0.170 |
Why?
|
| Etoposide | 1 | 2021 | 870 | 0.170 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2019 | 47 | 0.170 |
Why?
|
| Cell Differentiation | 4 | 2024 | 4078 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.160 |
Why?
|
| Animals | 19 | 2024 | 59536 | 0.160 |
Why?
|
| Aged, 80 and over | 16 | 2022 | 29902 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 476 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2022 | 842 | 0.160 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 24 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 1146 | 0.160 |
Why?
|
| Epithelium | 2 | 2019 | 720 | 0.160 |
Why?
|
| Gene Dosage | 4 | 2014 | 829 | 0.160 |
Why?
|
| Curriculum | 1 | 2023 | 860 | 0.160 |
Why?
|
| Platinum | 2 | 2022 | 138 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 673 | 0.150 |
Why?
|
| Jaagsiekte sheep retrovirus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 159 | 0.150 |
Why?
|
| Survival Analysis | 9 | 2021 | 9180 | 0.150 |
Why?
|
| Epithelial Cells | 2 | 2024 | 1818 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 1283 | 0.150 |
Why?
|
| Proteomics | 4 | 2022 | 1380 | 0.140 |
Why?
|
| DNA Damage | 3 | 2021 | 1954 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.140 |
Why?
|
| Secretin | 1 | 2015 | 25 | 0.140 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2014 | 153 | 0.140 |
Why?
|
| Software | 2 | 2022 | 1321 | 0.140 |
Why?
|
| Microbiota | 1 | 2022 | 547 | 0.140 |
Why?
|
| Proteome | 2 | 2017 | 561 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 5 | 2017 | 1077 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2020 | 1442 | 0.130 |
Why?
|
| Immunotherapy | 4 | 2023 | 3341 | 0.130 |
Why?
|
| Pneumonia | 2 | 2012 | 751 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2023 | 661 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 771 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 146 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 430 | 0.130 |
Why?
|
| Phenotype | 8 | 2022 | 6295 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 368 | 0.130 |
Why?
|
| Neoplasms | 3 | 2022 | 15193 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2023 | 5178 | 0.120 |
Why?
|
| Seminoma | 1 | 2014 | 81 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 1226 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 6009 | 0.120 |
Why?
|
| RNA | 4 | 2000 | 1013 | 0.120 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2023 | 33 | 0.120 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2014 | 123 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2013 | 22 | 0.120 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 249 | 0.110 |
Why?
|
| Cluster Analysis | 4 | 2022 | 1053 | 0.110 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.110 |
Why?
|
| Gene Expression | 3 | 2017 | 3570 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5112 | 0.110 |
Why?
|
| Biomarkers | 6 | 2023 | 5047 | 0.110 |
Why?
|
| Telomerase | 4 | 2000 | 525 | 0.110 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 199 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 7222 | 0.110 |
Why?
|
| Paraganglioma | 1 | 2014 | 170 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 2508 | 0.110 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2012 | 95 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 280 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2015 | 492 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 332 | 0.100 |
Why?
|
| Proteins | 1 | 2000 | 1963 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2023 | 1016 | 0.100 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 2283 | 0.100 |
Why?
|
| RNA, Messenger | 8 | 2021 | 6150 | 0.100 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 10001 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6207 | 0.100 |
Why?
|
| Blotting, Western | 4 | 2010 | 3536 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2173 | 0.100 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2010 | 39 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2023 | 9244 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 622 | 0.090 |
Why?
|
| Flap Endonucleases | 1 | 2010 | 26 | 0.090 |
Why?
|
| Octamer Transcription Factor-3 | 3 | 2019 | 107 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 423 | 0.090 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 489 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1165 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2024 | 2947 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.090 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2010 | 93 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 3101 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3552 | 0.090 |
Why?
|
| Adenoma | 3 | 1999 | 716 | 0.090 |
Why?
|
| Signal Transduction | 6 | 2021 | 11965 | 0.090 |
Why?
|
| Treatment Outcome | 10 | 2023 | 32848 | 0.090 |
Why?
|
| Clone Cells | 2 | 2021 | 555 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2010 | 241 | 0.080 |
Why?
|
| Chromosomal Instability | 2 | 2021 | 233 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 650 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2012 | 747 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 503 | 0.080 |
Why?
|
| Cyclin D1 | 1 | 2010 | 576 | 0.080 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 713 | 0.080 |
Why?
|
| Young Adult | 8 | 2019 | 21445 | 0.080 |
Why?
|
| Thyroid Nuclear Factor 1 | 2 | 2022 | 52 | 0.080 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 1960 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 3639 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1618 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 442 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 388 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2018 | 760 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3821 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 470 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 5395 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 612 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 521 | 0.070 |
Why?
|
| Melanoma | 1 | 2023 | 5317 | 0.070 |
Why?
|
| Piperazines | 4 | 2019 | 2101 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 2483 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2021 | 1681 | 0.070 |
Why?
|
| Disease Progression | 4 | 2021 | 6682 | 0.060 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2018 | 170 | 0.060 |
Why?
|
| Survival Rate | 4 | 2024 | 12221 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 1688 | 0.060 |
Why?
|
| Cell Cycle Proteins | 3 | 2004 | 2045 | 0.060 |
Why?
|
| Phthalazines | 2 | 2019 | 253 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.060 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2024 | 46 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1294 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2021 | 2588 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 1121 | 0.060 |
Why?
|
| Homozygote | 2 | 2020 | 717 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2010 | 1549 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2023 | 37905 | 0.060 |
Why?
|
| Propionates | 1 | 2022 | 71 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 3890 | 0.050 |
Why?
|
| Loss of Heterozygosity | 2 | 2021 | 602 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2024 | 369 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 57 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2022 | 149 | 0.050 |
Why?
|
| Ketones | 1 | 2022 | 54 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 829 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2021 | 4307 | 0.050 |
Why?
|
| Cell Movement | 3 | 2018 | 2466 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2022 | 192 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 111 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 4 | 2018 | 6942 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 287 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 134 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 46 | 0.050 |
Why?
|
| Gastric Mucosa | 3 | 2000 | 613 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 1999 | 2022 | 0.050 |
Why?
|
| Catalytic Domain | 2 | 1999 | 303 | 0.050 |
Why?
|
| Recurrence | 2 | 2023 | 4758 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2023 | 2488 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2023 | 1620 | 0.050 |
Why?
|
| Trefoil Factor-1 | 1 | 2000 | 15 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 490 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 43 | 0.050 |
Why?
|
| Chromogranins | 1 | 2020 | 84 | 0.050 |
Why?
|
| Nicotine | 1 | 2022 | 244 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 212 | 0.050 |
Why?
|
| Web Browser | 1 | 2019 | 17 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2019 | 666 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2021 | 223 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 2 | 1999 | 534 | 0.040 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2019 | 29 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 185 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3168 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1443 | 0.040 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 483 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 251 | 0.040 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2019 | 76 | 0.040 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 45 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 206 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2021 | 546 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 69 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 671 | 0.040 |
Why?
|
| Genes, ras | 2 | 2015 | 667 | 0.040 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2020 | 253 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 298 | 0.040 |
Why?
|
| Teaching | 1 | 2020 | 243 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Imatinib Mesylate | 2 | 2013 | 1665 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2020 | 429 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 4557 | 0.040 |
Why?
|
| Keratins | 1 | 2019 | 330 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1819 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 2291 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 172 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 84 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 1144 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 267 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 703 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 437 | 0.040 |
Why?
|
| Benzamides | 2 | 2013 | 1832 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 1998 | 249 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2010 | 886 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2017 | 117 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2000 | 974 | 0.040 |
Why?
|
| E2F Transcription Factors | 3 | 2004 | 132 | 0.040 |
Why?
|
| Thymectomy | 1 | 2017 | 79 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2017 | 42 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 733 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 182 | 0.040 |
Why?
|
| Pathologists | 1 | 2017 | 91 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 677 | 0.040 |
Why?
|
| Biopsy | 2 | 2016 | 3443 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 856 | 0.040 |
Why?
|
| Phylogeny | 1 | 2019 | 826 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 236 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 3976 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 235 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 177 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 276 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 342 | 0.030 |
Why?
|
| Alleles | 2 | 2019 | 2437 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2023 | 1756 | 0.030 |
Why?
|
| Pyrazines | 1 | 2019 | 495 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 506 | 0.030 |
Why?
|
| E2F1 Transcription Factor | 3 | 2004 | 206 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 675 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 182 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 207 | 0.030 |
Why?
|
| Adolescent | 3 | 2023 | 31252 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4757 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 461 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Colon | 1 | 1999 | 670 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Keratin-6 | 1 | 2014 | 39 | 0.030 |
Why?
|
| Keratin-5 | 1 | 2014 | 57 | 0.030 |
Why?
|
| SOXF Transcription Factors | 1 | 2014 | 34 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2017 | 244 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2330 | 0.030 |
Why?
|
| PAX8 Transcription Factor | 1 | 2014 | 55 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2014 | 79 | 0.030 |
Why?
|
| Glypicans | 1 | 2014 | 51 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 588 | 0.030 |
Why?
|
| Chromogranin A | 1 | 2014 | 65 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 323 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 889 | 0.030 |
Why?
|
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2014 | 8 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 1301 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 160 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 134 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2015 | 229 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 629 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 146 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 1385 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 838 | 0.030 |
Why?
|
| Cadherins | 1 | 2017 | 660 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 102 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 2693 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 1493 | 0.030 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2013 | 41 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2013 | 104 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 1999 | 3578 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 130 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 633 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 151 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 518 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 734 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 313 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 392 | 0.030 |
Why?
|
| Epiregulin | 1 | 2012 | 14 | 0.030 |
Why?
|
| EGF Family of Proteins | 1 | 2012 | 28 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 4744 | 0.030 |
Why?
|
| Amphiregulin | 1 | 2012 | 32 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 142 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 229 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 541 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 259 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2084 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2012 | 126 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 280 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 365 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 80 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2011 | 13 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2011 | 10 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2011 | 14 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 783 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 4298 | 0.020 |
Why?
|
| Lung Injury | 1 | 2012 | 131 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 483 | 0.020 |
Why?
|
| Apoptosis | 2 | 2019 | 7591 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 134 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 12926 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 324 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 2265 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 460 | 0.020 |
Why?
|
| Pyrimidines | 2 | 2013 | 3518 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2019 | 1471 | 0.020 |
Why?
|
| Nanog Homeobox Protein | 1 | 2010 | 65 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 1320 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 191 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 2 | 1999 | 54 | 0.020 |
Why?
|
| Transcription Factor DP1 | 2 | 1999 | 57 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 157 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 3981 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 2139 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 4053 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2012 | 474 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 927 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 1999 | 287 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1987 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 3045 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 967 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 231 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2054 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 2450 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2010 | 875 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 1489 | 0.020 |
Why?
|
| Carcinoma | 1 | 1999 | 2578 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 4549 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 682 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 1009 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 770 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 1764 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6100 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 14889 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8865 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 5539 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1546 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1037 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2314 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 1062 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 301 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 501 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 408 | 0.020 |
Why?
|
| Cell Division | 2 | 1999 | 2489 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.020 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 9 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 1143 | 0.020 |
Why?
|
| Thymidine Phosphorylase | 1 | 2004 | 23 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 53 | 0.010 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2004 | 72 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4367 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2216 | 0.010 |
Why?
|
| Macrophages | 1 | 2010 | 1304 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2004 | 196 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 2944 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7551 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| Kidney | 1 | 2010 | 2146 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 17523 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 999 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 1999 | 4844 | 0.010 |
Why?
|
| Tumor Protein p73 | 1 | 1999 | 105 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2004 | 1944 | 0.010 |
Why?
|
| Gastric Fundus | 1 | 1998 | 19 | 0.010 |
Why?
|
| Metaplasia | 1 | 1999 | 383 | 0.010 |
Why?
|
| Child | 1 | 2019 | 29154 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1999 | 825 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 1328 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1999 | 1234 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1999 | 1081 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 6089 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1998 | 2086 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1999 | 2967 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 4320 | 0.000 |
Why?
|